Advertisement

Topics

Allergan's Brent Saunders Is Charging Into Medical Aesthetics. Should Others Follow?

04:04 EDT 8 Aug 2017 | Forbes

Allergan is not abandoning R&D in major diseases. Rather, it has 35% of its portfolio in relatively low-risk, lower cost R&D that can sustain its investments in far more challenging therapeutic areas.

Original Article: Allergan's Brent Saunders Is Charging Into Medical Aesthetics. Should Others Follow?

NEXT ARTICLE

More From BioPortfolio on "Allergan's Brent Saunders Is Charging Into Medical Aesthetics. Should Others Follow?"

Quick Search
Advertisement